Yi Kun Don, Cai Zu Yun, Covey Douglas F, Simpkins James W
Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, TX 76107, USA.
J Pharmacol Exp Ther. 2008 Mar;324(3):1188-95. doi: 10.1124/jpet.107.132308. Epub 2007 Dec 18.
The mechanism of estrogen-mediated neuroprotection is not yet clear. Estrogens have a variety of modes of action, including transducing signaling events such as activation and/or suppression of the mitogen-activated protein kinase (MAPK) pathway. We have previously shown protein phosphatases to be involved in 17beta-estradiol-mediated neuroprotection. In the present study, we assessed the role of estrogen receptors (ERs) in estrogen-mediated neuroprotection from oxidative/excitotoxic stress and the consequential effects on MAPK signaling. Okadaic acid and calyculin A, nonspecific serine/threonine phosphatase inhibitors, were exposed to cells at various concentrations in the presence or absence of 17alpha-estradiol, the enantiomer of 17beta-estradiol, 2-(1-adamantyl)-3-hydroxyestra-1,3,5(10)-trien-17-one (ZYC3; non-ER-binding estrogen analog), and/or glutamate. All three compounds, which we have shown to have little or no binding to ERalpha and ERbeta, were protective against glutamate toxicity but not against okadaic acid and calyculin A toxicity. In addition, in the presence of effective concentrations of these inhibitors, the protective effects of these estrogen analogs were lost. Glutamate treatment caused a 50% decrease in levels of protein phosphatase 1 (PP1), protein phosphatase 2A (PP2A), and protein phosphatase 2B (calcineurin) (PP2B). Coadministration of ZYC3 with glutamate prevented the decreases in PP1, PP2A, and PP2B levels. Furthermore, glutamate treatment caused a persistent increase in phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 that corresponds with the decrease protein levels of serine/threonine phosphatases. ZYC3 blocked this persistent increase in ERK phosphorylation. These results suggest that estrogens protect cells against glutamate-induced oxidative stress through an ER-independent mediated mechanism that serves to preserve phosphatase activity in the face of oxidative insults, resulting in attenuation of the persistent phosphorylation of ERK associated with neuronal death.
雌激素介导的神经保护机制尚不清楚。雌激素具有多种作用模式,包括转导信号事件,如激活和/或抑制丝裂原活化蛋白激酶(MAPK)途径。我们之前已经表明蛋白磷酸酶参与17β-雌二醇介导的神经保护。在本研究中,我们评估了雌激素受体(ERs)在雌激素介导的针对氧化/兴奋性毒性应激的神经保护中的作用以及对MAPK信号传导的后续影响。在存在或不存在17α-雌二醇(17β-雌二醇的对映体)、2-(1-金刚烷基)-3-羟基雌-1,3,5(10)-三烯-17-酮(ZYC3;非ER结合雌激素类似物)和/或谷氨酸的情况下,将冈田酸和花萼海绵诱癌素A(非特异性丝氨酸/苏氨酸磷酸酶抑制剂)以不同浓度作用于细胞。我们已表明这三种化合物与ERα和ERβ几乎没有或没有结合,它们对谷氨酸毒性具有保护作用,但对冈田酸和花萼海绵诱癌素A毒性没有保护作用。此外,在这些抑制剂的有效浓度存在下,这些雌激素类似物的保护作用丧失。谷氨酸处理导致蛋白磷酸酶1(PP1)、蛋白磷酸酶2A(PP2A)和蛋白磷酸酶2B(钙调神经磷酸酶)(PP2B)水平降低50%。ZYC3与谷氨酸共同给药可防止PP1、PP2A和PP2B水平降低。此外,谷氨酸处理导致细胞外信号调节激酶(ERK)1/2的磷酸化持续增加,这与丝氨酸/苏氨酸磷酸酶的蛋白水平降低相对应。ZYC3阻断了ERK磷酸化的这种持续增加。这些结果表明,雌激素通过一种不依赖ER的介导机制保护细胞免受谷氨酸诱导的氧化应激,该机制在面对氧化损伤时有助于维持磷酸酶活性,从而导致与神经元死亡相关的ERK持续磷酸化减弱。